Axonics Modulation Technologies (NASDAQ:AXNX) initiated with Overweight rating at Piper Jaffray.
Homology Medicines (NASDAQ:FIXX) initiated with Market Perform rating at Oppenheimer.
Sarepta Therapeutics (NASDAQ:SRPT) initiated with Buy rating and $183 (120% upside) price target at Guggenheim. Shares up 2% premarket.
Takeda ADRs (NYSE:TAK) initiated with Market Perform rating and $19.50 (9% upside) price target at Cowen and Company.
Wave Life Sciences (NASDAQ:WVE) initiated with Buy rating and $43 (70% upside) price target at Guggenheim.
Y-mAbs Therapeutics (NASDAQ:YMAB) resumed with Buy rating and $35 (12% upside) price target at BofA Merrill Lynch.
Amedisys (NASDAQ:AMED) upgraded to Outperform with a $160 (24% upside) price target at Baird.
Chemed (NYSE:CHE) upgraded to Market Perform with a $490 (24% upside) price target at JMP Securities.
Intellia Therapeutics (NASDAQ:NTLA) upgraded to Outperform at Raymond James. Shares up 4% premarket.
Celgene (NASDAQ:CELG) downgraded to Neutral with a $101 (6% downside risk) price target at Baird.
Eidos Therapeutics (NASDAQ:EIDX) downgraded to Equal Weight with a $45 (7% downside risk) price target at Barclays.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.